Sofosbuvir/Velpatasvir and Mental Health Impact in people with Lived Experience and Hepatitis C infection - SMILE-C Trial
Phase of Trial: Phase IV
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SMILE-C
- Sponsors Gilead Sciences
- 05 Nov 2019 Planned End Date changed from 22 Feb 2021 to 28 Feb 2022.
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.
- 04 Dec 2018 New trial record